Report Detail

Request for Sample of this report

Other Global Circular RNA Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

  • RnM4724343
    • |
  • 21 July, 2026
    • |
  • Global
    • |
  • 87 Pages
    • |
  • GIR
    • |
  • Other

According to our (Global Info Research) latest study, the global Circular RNA Drugs market size was valued at US$ 49.39 million in 2025 and is forecast to a readjusted size of US$ 503 million by 2032 with a CAGR of 38.6% during review period.
Circular RNA drugs are an emerging class of RNA therapeutics that use engineered circular RNA as the core active ingredient or expression vector. These products are generally developed through sequence design, in vitro transcription, circularization, purification, delivery formulation development, and GMP scale-up manufacturing to form drug candidates. Key application areas include therapeutic vaccines, protein-expression therapies, in vivo CAR-T, cancer immunotherapy, ischemic disease repair, and rare disease treatment. Upstream materials mainly include nucleotide raw materials, modified nucleosides, enzymes, plasmid templates, buffers, chromatography media, single-use bioprocessing consumables, lipid nanoparticle materials, analytical testing reagents, and sterile filling and packaging materials. Downstream customers mainly include innovative pharmaceutical companies, RNA drug platform companies, vaccine companies, CRO/CDMO providers, hospital clinical research centers, and collaborative projects with large pharmaceutical companies.
The current circular RNA drugs market remains at an early stage of clinical translation, with industry activity mainly focused on platform validation, candidate selection, circularization process optimization, delivery system development, and clinical safety evaluation. Compared with traditional small-molecule drugs, antibody drugs, and some commercialized mRNA vaccines, circular RNA drugs have not yet established a large-scale end-market sales model. Company value is still mainly reflected in technology platforms, pipeline progress, patent coverage, collaborative R&D capability, and CMC scale-up capability. At this stage, the number of core global players remains limited, with major participants concentrated in the United States and China, while European companies are more active in virus-vector-based circular RNA expression and gene therapy-related directions. Overall, the industry remains an emerging field with high R&D intensity, high technical barriers, and significant uncertainty.
Future development will be centered on the transition from platform concept to clinical validation. Early-stage companies have mainly emphasized the theoretical advantages of circular RNA in stability, expression duration, and programmability, while the next phase of competition will focus more on safety, efficacy, immunogenicity control, and dose-response performance in human studies. As more candidates enter clinical development, the industry is expected to gradually form application clusters around therapeutic vaccines, in vivo cell therapy, local tissue repair, protein-expression therapy, and rare disease treatment. At the same time, circularization efficiency, RNA purity, impurity control, tissue selectivity of LNP or other delivery systems, and consistency in GMP scale-up manufacturing will become key factors determining whether a company can evolve from a research platform into a drug developer.
Market growth is mainly driven by the evolution of RNA drug technologies, unmet clinical needs, capital support, large-pharma collaboration, accumulating regulatory experience, and progress in biomanufacturing processes. Compared with linear mRNA, circular RNA may offer a longer expression window and potentially lower dosing frequency, giving it differentiated value in scenarios that require sustained therapeutic protein expression or localized release of functional factors. Cancer immunotherapy, autoimmune diseases, ischemic cardiovascular diseases, rare diseases, and in vivo CAR-T are likely to become important early validation areas. The growing interest of large pharmaceutical companies in next-generation RNA platforms may also support more licensing deals, acquisitions, and co-development programs, providing small and mid-sized platform companies with funding, clinical development resources, and global registration capabilities.
The main barriers lie in the still-evolving technical maturity, clinical validation, and industrialization pathway. Although circular RNA has potential advantages in molecular stability, its in vivo translation efficiency, delivery efficiency, immune response, long-term safety, and controllability of expression across different tissues still require systematic validation. On the manufacturing side, companies also face challenges related to circularization yield, removal of linear RNA and by-products, batch-to-batch consistency, quality standard development, and cost control. Regulatory review pathways for circular RNA drugs are still being shaped, and differences among technical routes may affect clinical filing and quality-control requirements. Therefore, while the industry has strong long-term growth potential, it is likely to remain R&D-driven in the near term, with significant project differentiation and a high attrition rate.
The Circular RNA Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Circular RNA Drugs market is split by Type and by Application. For the period 2026-2032, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type,
Protein Expression Therapeutics
Therapeutic Vaccines
Other
Market segment by Delivery Technology
Lipid Nanoparticle Delivery
Local Direct Delivery
Other
Market segment by Route of Administration
Intravenous Administration
Local Injection
Other
Market segment by Application
Pharmaceutical and Biotechnology Companies
Research Institutes
Other
Market segment by players, this report covers
Orna Therapeutics
RiboX Therapeutics
Sail Biomedicines
Chimerna Therapeutics
Torque Bio
Circurna
Shanghai CirCode Biomed
Therorna
Circio Holding
Market segment by regions, regional analysis covers
North America
Europe
Asia-Pacific (China, Japan, South Korea, Rest of Asia)
South America
Middle East & Africa


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Circular RNA Drugs by Type
    • 1.3.1 Overview: Global Circular RNA Drugs Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Circular RNA Drugs Consumption Value Market Share by Type in 2025
    • 1.3.3 Protein Expression Therapeutics
    • 1.3.4 Therapeutic Vaccines
    • 1.3.5 Other
  • 1.4 Classification of Circular RNA Drugs by Delivery Technology
    • 1.4.1 Overview: Global Circular RNA Drugs Market Size by Delivery Technology: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Circular RNA Drugs Consumption Value Market Share by Delivery Technology in 2025
    • 1.4.3 Lipid Nanoparticle Delivery
    • 1.4.4 Local Direct Delivery
    • 1.4.5 Other
  • 1.5 Classification of Circular RNA Drugs by Route of Administration
    • 1.5.1 Overview: Global Circular RNA Drugs Market Size by Route of Administration: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Circular RNA Drugs Consumption Value Market Share by Route of Administration in 2025
    • 1.5.3 Intravenous Administration
    • 1.5.4 Local Injection
    • 1.5.5 Other
  • 1.6 Global Circular RNA Drugs Market by Application
    • 1.6.1 Overview: Global Circular RNA Drugs Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Pharmaceutical and Biotechnology Companies
    • 1.6.3 Research Institutes
    • 1.6.4 Other
  • 1.7 Global Circular RNA Drugs Market Size & Forecast
  • 1.8 Global Circular RNA Drugs Market Size and Forecast by Region
    • 1.8.1 Global Circular RNA Drugs Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Circular RNA Drugs Market Size by Region, (2021-2032)
    • 1.8.3 North America Circular RNA Drugs Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Circular RNA Drugs Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Circular RNA Drugs Market Size and Prospect (2021-2032)
    • 1.8.6 South America Circular RNA Drugs Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Circular RNA Drugs Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Orna Therapeutics
    • 2.1.1 Orna Therapeutics Details
    • 2.1.2 Orna Therapeutics Major Business
    • 2.1.3 Orna Therapeutics Circular RNA Drugs Product and Solutions
    • 2.1.4 Orna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Orna Therapeutics Recent Developments and Future Plans
  • 2.2 RiboX Therapeutics
    • 2.2.1 RiboX Therapeutics Details
    • 2.2.2 RiboX Therapeutics Major Business
    • 2.2.3 RiboX Therapeutics Circular RNA Drugs Product and Solutions
    • 2.2.4 RiboX Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 RiboX Therapeutics Recent Developments and Future Plans
  • 2.3 Sail Biomedicines
    • 2.3.1 Sail Biomedicines Details
    • 2.3.2 Sail Biomedicines Major Business
    • 2.3.3 Sail Biomedicines Circular RNA Drugs Product and Solutions
    • 2.3.4 Sail Biomedicines Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sail Biomedicines Recent Developments and Future Plans
  • 2.4 Chimerna Therapeutics
    • 2.4.1 Chimerna Therapeutics Details
    • 2.4.2 Chimerna Therapeutics Major Business
    • 2.4.3 Chimerna Therapeutics Circular RNA Drugs Product and Solutions
    • 2.4.4 Chimerna Therapeutics Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Chimerna Therapeutics Recent Developments and Future Plans
  • 2.5 Torque Bio
    • 2.5.1 Torque Bio Details
    • 2.5.2 Torque Bio Major Business
    • 2.5.3 Torque Bio Circular RNA Drugs Product and Solutions
    • 2.5.4 Torque Bio Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Torque Bio Recent Developments and Future Plans
  • 2.6 Circurna
    • 2.6.1 Circurna Details
    • 2.6.2 Circurna Major Business
    • 2.6.3 Circurna Circular RNA Drugs Product and Solutions
    • 2.6.4 Circurna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Circurna Recent Developments and Future Plans
  • 2.7 Shanghai CirCode Biomed
    • 2.7.1 Shanghai CirCode Biomed Details
    • 2.7.2 Shanghai CirCode Biomed Major Business
    • 2.7.3 Shanghai CirCode Biomed Circular RNA Drugs Product and Solutions
    • 2.7.4 Shanghai CirCode Biomed Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Shanghai CirCode Biomed Recent Developments and Future Plans
  • 2.8 Therorna
    • 2.8.1 Therorna Details
    • 2.8.2 Therorna Major Business
    • 2.8.3 Therorna Circular RNA Drugs Product and Solutions
    • 2.8.4 Therorna Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Therorna Recent Developments and Future Plans
  • 2.9 Circio Holding
    • 2.9.1 Circio Holding Details
    • 2.9.2 Circio Holding Major Business
    • 2.9.3 Circio Holding Circular RNA Drugs Product and Solutions
    • 2.9.4 Circio Holding Circular RNA Drugs Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Circio Holding Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Circular RNA Drugs Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Circular RNA Drugs by Company Revenue
    • 3.2.2 Top 3 Circular RNA Drugs Players Market Share in 2025
    • 3.2.3 Top 6 Circular RNA Drugs Players Market Share in 2025
  • 3.3 Circular RNA Drugs Market: Overall Company Footprint Analysis
    • 3.3.1 Circular RNA Drugs Market: Region Footprint
    • 3.3.2 Circular RNA Drugs Market: Company Product Type Footprint
    • 3.3.3 Circular RNA Drugs Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Circular RNA Drugs Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Circular RNA Drugs Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Circular RNA Drugs Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Circular RNA Drugs Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Circular RNA Drugs Consumption Value by Type (2021-2032)
  • 6.2 North America Circular RNA Drugs Market Size by Application (2021-2032)
  • 6.3 North America Circular RNA Drugs Market Size by Country
    • 6.3.1 North America Circular RNA Drugs Consumption Value by Country (2021-2032)
    • 6.3.2 United States Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Circular RNA Drugs Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Circular RNA Drugs Consumption Value by Type (2021-2032)
  • 7.2 Europe Circular RNA Drugs Consumption Value by Application (2021-2032)
  • 7.3 Europe Circular RNA Drugs Market Size by Country
    • 7.3.1 Europe Circular RNA Drugs Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 7.3.3 France Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Circular RNA Drugs Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Circular RNA Drugs Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Circular RNA Drugs Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Circular RNA Drugs Market Size by Region
    • 8.3.1 Asia-Pacific Circular RNA Drugs Consumption Value by Region (2021-2032)
    • 8.3.2 China Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 8.3.5 India Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Circular RNA Drugs Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Circular RNA Drugs Consumption Value by Type (2021-2032)
  • 9.2 South America Circular RNA Drugs Consumption Value by Application (2021-2032)
  • 9.3 South America Circular RNA Drugs Market Size by Country
    • 9.3.1 South America Circular RNA Drugs Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Circular RNA Drugs Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Circular RNA Drugs Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Circular RNA Drugs Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Circular RNA Drugs Market Size by Country
    • 10.3.1 Middle East & Africa Circular RNA Drugs Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Circular RNA Drugs Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Circular RNA Drugs Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Circular RNA Drugs Market Drivers
  • 11.2 Circular RNA Drugs Market Restraints
  • 11.3 Circular RNA Drugs Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Circular RNA Drugs Industry Chain
  • 12.2 Circular RNA Drugs Upstream Analysis
  • 12.3 Circular RNA Drugs Midstream Analysis
  • 12.4 Circular RNA Drugs Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Circular RNA Drugs. Industry analysis & Market Report on Circular RNA Drugs is a syndicated market report, published as Global Circular RNA Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Circular RNA Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo